Paper Details

  1. Home
  2. Paper Details

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Author: , Al-AssiM Tarek, AnDi, BennettMichael, BrainardDiana, EversonGregory, FeldJordan, GordonStuart C, JacobsonIra M, KowdleyKris V, LawitzEric, LinMing, McHutchisonJohn G, McNallyJohn, NelsonDavid R, PatelKeyur, PiankoStephen, Rodriguez-TorresMaribel, SchiffEugene, ShiffmanMitchell L, SubramanianG Mani, SulkowskiMark S, SymondsWilliam T, YoshidaEric M

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Currently, there are no approved treatments for people with chronic hepatitis C virus (HCV) infection of genotypes 2 or 3 who cannot take peginterferon or have not responded to interferon treatment. Early research with a new medication called sofosbuvir, taken by mouth, shows promise for treating these types of HCV infections.
Paper Details　
Original Abstract of the Article :
Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options. In phase 2 trials, regimens including the oral nucleotide pol...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1214854

データ提供：米国国立医学図書館（NLM）

Sofosbuvir for Hepatitis C Genotype 2 or 3: A Camel's Perspective

The [desert of hepatitis C] is a vast and unforgiving landscape, with [viral infection] like a relentless sandstorm. This research, like a camel caravan seeking to [find a cure for this debilitating disease], explores the use of [sofosbuvir] to [treat hepatitis C genotype 2 or 3]. The researchers found that [sofosbuvir] was [effective] in [achieving sustained virological response] in many patients, potentially offering a glimmer of hope for those who have been struggling with this chronic infection.

A Promising Oasis in the Desert of Hepatitis C

This study, like a camel caravan discovering a hidden oasis in the desert, highlights the potential of [sofosbuvir] to [treat hepatitis C genotype 2 or 3]. The findings suggest that this [drug] can [significantly improve] the lives of many patients by [eliminating the virus] and [reducing the risk of liver disease]. However, it's important to [understand the limitations] of this treatment and to [continue monitoring] for any potential complications.

Navigating the Desert of Hepatitis C

This research, like a camel caravan navigating a challenging desert, reminds us of the importance of [continued research and development] in the fight against [hepatitis C]. By understanding the [molecular mechanisms] of this disease and developing [new therapies], we can continue to find new oases in the desert of hepatitis C.

Dr. Camel's Conclusion

This study, like a camel caravan venturing into uncharted territory, offers a promising new path for those facing the [challenges of hepatitis C]. While [sofosbuvir] may not be a magic bullet, it represents a [significant advancement] in the treatment of this complex disease. By continuing to research and develop new therapies, we can strive to create a more hospitable landscape for those living with hepatitis C.

Date :
  1. Date Completed 2013-05-28
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

23607593

DOI: Digital Object Identifier

10.1056/NEJMoa1214854

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.